Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

33%

Ph phase_1

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Detailed Status

Completed1

Not yet recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

completed133%

not_yet_recruiting133%

active_not_recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

completedphase_1

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

NCT07456800

not_yet_recruitingphase_3

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT07284602

active_not_recruitingphase_2

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05321420

Clinical Trials (3)

Showing 3 of 3 trials

NCT07456800Phase 1

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

Completed

NCT07284602Phase 3

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Not Yet Recruiting

NCT05321420Phase 2

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3